Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last1,921 to 1,940 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Dronedarone 400mg Bid vs Placebo: First Hospitalization for Cardiovascular Reason | 675 of 2,301 859 of 2,327 | -7.6 points -10.3 to -4.9 | 4,628 | NCT00174785 A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation |
| Dronedarone 400mg Bid vs Placebo: Death From Any Cause | 116 of 2,301 139 of 2,327 | -0.9 points -2.3 to 0.4 | 4,628 | NCT00174785 A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation |
| Dronedarone 400mg Bid vs Placebo: Adjudicated Cardiovascular Death | 63 of 2,301 90 of 2,327 | -1.1 points -2.2 to -0.1 | 4,628 | NCT00174785 A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation |
| AZD7442 vs Placebo: Incidence of ADA to AZD7442 in Serum | 403 of 3,086 34 of 1,540 | 10.9 points 9.4 to 12.2 | 4,626 | NCT04625725 Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. |
| Dronedarone 400mg Bid vs Placebo: serious adverse events | 456 of 2,291 489 of 2,313 | -1.2 points -3.6 to 1.1 | 4,604 | NCT00174785 A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation |
| Pharmacist Arm vs Usual Care: Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Including Hospitals at Least Statewide) | 595 of 2,288 610 of 2,314 | -0.4 points -2.9 to 2.2 | 4,602 | NCT04071951 Pharmacist Intervention to Reduce Post-Hospitalization Utilization |
| Adolescent Records - Intervention Exposed vs Adolescent Records - Unexposed: Retention in HIV Care | 1,570 of 2,123 1,855 of 2,472 | -1.1 points -3.6 to 1.4 | 4,595 | NCT02928900 Patient Actor Training to Improve HIV Services for Adolescents in Kenya |
| Treatment - Participation in Nurse Family Partnership vs Control: Number of Participants With an Ultrasound at 18-22 Weeks | 2,293 of 3,065 1,134 of 1,522 | 0.3 points -2.3 to 3.0 | 4,587 | NCT03360539 Nurse-Family Partnership Impact Evaluation in South Carolina |
| Treatment - Participation in Nurse Family Partnership vs Control: Number of Participants Who Received Adequate Prenatal Care | 2,572 of 3,065 1,283 of 1,522 | -0.4 points -2.6 to 1.9 | 4,587 | NCT03360539 Nurse-Family Partnership Impact Evaluation in South Carolina |
| Treatment - Participation in Nurse Family Partnership vs Control: Number of Participants With a Dental Visit During Pregnancy | 625 of 3,065 275 of 1,522 | 2.3 points -0.1 to 4.7 | 4,587 | NCT03360539 Nurse-Family Partnership Impact Evaluation in South Carolina |
| Pregnant Women vs Non-Pregnant Women: Positive Berlin Questionnaire Indicative of Sleep Disordered Breathing | 1,343 of 4,074 96 of 503 | 13.9 points 9.9 to 17.4 | 4,577 | NCT00462306 Incidence of Obstructive Sleep Apnea in Pregnancy |
| Cabotegravir vs TDF/FTC: deaths from any cause | 4 of 2,281 7 of 2,285 | -0.1 points -0.5 to 0.2 | 4,566 | NCT02720094 Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men |
| Cabotegravir vs TDF/FTC: serious adverse events | 117 of 2,281 109 of 2,285 | 0.4 points -0.9 to 1.6 | 4,566 | NCT02720094 Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men |
| Cabotegravir vs TDF/FTC: Number of Participants Experiencing Grade 2 or Higher Clinical and Laboratory Adverse Events | 2,106 of 2,280 2,116 of 2,282 | -0.4 points -1.9 to 1.2 | 4,562 | NCT02720094 Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men |
| Cabotegravir vs TDF/FTC: Number of Participants With Grade 3 or 4 Liver-related Adverse Events (AEs) | 73 of 2,280 96 of 2,282 | -1.0 points -2.1 to 0.1 | 4,562 | NCT02720094 Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men |
| Cabotegravir vs TDF/FTC: Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 | 13 of 2,280 39 of 2,281 | -1.1 points -1.8 to -0.5 | 4,561 | NCT02720094 Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men |
| Participants Treated With Oseltamivir vs Participants Not Treated With Oseltamivir: serious adverse events | 24 of 2,578 11 of 1,975 | 0.4 points -0.2 to 0.9 | 4,553 | NCT00884117 Influenza Resistance Information Study |
| Denosumab / Denosumab vs Placebo / Denosumab: Number of Participants With Non-Vertebral Fractures | 172 of 2,343 219 of 2,207 | -2.6 points -4.2 to -1.0 | 4,550 | NCT00523341 Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis |
| Denosumab / Denosumab vs Placebo / Denosumab: Number of Participants With Antibodies to Denosumab | 0 of 2,343 1 of 2,206 | -0.0 points -0.3 to 0.1 | 4,549 | NCT00523341 Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis |
| Denosumab/ Denosumab 60 mg Q6M vs Placebo/ Denosumab 60 mg Q6M: serious adverse events | 1,014 of 2,343 945 of 2,206 | 0.4 points -2.4 to 3.3 | 4,549 | NCT00523341 Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis |
Code
curl "https://conductscience.org/api/comparisons/v1?page=97"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=97
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00174785-8a9b5021",
"title": "Dronedarone 400mg Bid vs Placebo: First Hospitalization for Cardiovascular Reason",
"summary": "675 of 2301 against 859 of 2327; risk difference -7.6 points, 95% interval -10.3 to -4.9; NCT00174785, A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation",
"record": "/library/comparisons/NCT00174785-8a9b5021",
"nct_id": "NCT00174785",
"kind": "outcome",
"participants": 4628,
"risk_difference": {
"value": -0.0757941045792575,
"lower": -0.10272508349976558,
"upper": -0.04870187898795293
},
"group_1": "675 of 2,301",
"group_2": "859 of 2,327",
"difference": "-7.6 points",
"interval": "-10.3 to -4.9",
"trial_title": "A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation"
},
{
"id": "NCT00174785-d622aee0",
"title": "Dronedarone 400mg Bid vs Placebo: Death From Any Cause",
"summary": "116 of 2301 against 139 of 2327; risk difference -0.9 points, 95% interval -2.3 to 0.4; NCT00174785, A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation",
"record": "/library/comparisons/NCT00174785-d622aee0",
"nct_id": "NCT00174785",
"kind": "outcome",
"participants": 4628,
"risk_difference": {
"value": -0.009320698554672609,
"lower": -0.02255314169192054,
"upper": 0.003868715407865075
},
"group_1": "116 of 2,301",
"group_2": "139 of 2,327",
"difference": "-0.9 points",
"interval": "-2.3 to 0.4",
"trial_title": "A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=98",
"request_id": "Clg6rseKPMDB_Vc0"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant